You just read:

U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

May 22, 2019, 09:03 ET